On Thursday, 10x Genomics got a positive adjustment to its Relative Strength (RS) Rating, from 78 to 83.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating north of 80 as they begin their biggest price moves.
While it's not currently an ideal time to jump in, see if the stock is able to establish and enter a buying range in heavy volume.
10x Genomics showed 0% EPS growth in its most recent report. Revenue increased 13%.
10x Genomics earns the No. 28 rank among its peers in the Medical-Products industry group. Insulet, TransMedics Group and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
